Top > News Releases

CONTACT : John Wulf
COO/CBO, Y's Therapeutics Co., Ltd.
President, Y's Therapeutics, Inc
+1-650-777-7770
bizdev@ysthera.com

Y's Therapeutics Raises 2.3 billion yen (US $20 million) in Series D Financing

Tokyo, Japan - October 3, 2006 - Y's Therapeutics Co., Ltd., a privately held biopharmaceutical company, today announced it has raised a total of 2.3 billion yen (US $20 million) through a Series D financing from new and existing investors since March 2006. Key investors in this financing included SBI Investment Co., Ltd. (through its managed investment fund). “The 2.3 billion yen raised through this financing will enable us to further accelerate the development of two main projects, YSPSL and YSCMA.” noted Nobuo Kato, Representative Director, Y's Therapeutics Co., Ltd.

YSPSL (rPSGL-Ig) is a clinical-stage recombinant molecule resulting from fusion of P-selectin glycoprotein ligand-1 (PSGL-1) to human IgG1. It is currently under evaluation for the prophylaxis of DGF following kidney transplantation. YSCMA is a preclinical stage humanized monoclonal antibody project targeted for the treatment of solid tumors and hematological cancers.



About Y’s Therapeutics
Y’s Therapeutics (http://www.ysthera.com) is a privately held biopharmaceutical company engaged in the R&D of novel therapeutics for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. Y’s focuses on the development of preclinical and early-stage clinical projects pursued through research collaborations and in-licensing opportunities from academic institutions and biotech companies. Y’s intends to seek collaborative relationships, including out-licensing of product rights and creation of joint ventures, for late-stage development, manufacturing and commercialization of its portfolio products. The company currently has several projects in its clinical and preclinical pipeline.

Top  |  Site Map  |  Access Map  |  Privacy Policy  |  Terms of Use